Effects of PUVA and mechlorethamine treatment of psoriatic patients on epidermal Langerhans' cells

Using OKT6 monoclonal antibody, we investigated the number of epidermal Langerhans' cells (LCs) in involved skin from patients with psoriasis, before and after mechlorethamine (HN2) or PUVA treatment. The number of LCs remained at about pretreatment number during three weeks of HN2 treatment al...

Full description

Saved in:
Bibliographic Details
Published inActa dermato-venereologica Vol. 67; no. 6; pp. 532 - 535
Main Authors TORINUKI, W, MAUDUIT, G, HAFTEK, M, THIVOLET, J
Format Journal Article
LanguageEnglish
Published Uppsala Acta dermato-venereologica 01.01.1987
Subjects
Antibodies, Monoclonal - immunology
Biological and medical sciences
Humans
Langerhans Cells - drug effects
Langerhans Cells - immunology
Mechlorethamine - therapeutic use
Medical sciences
Pharmacology. Drug treatments
Psoriasis - drug therapy
Psoriasis - immunology
PUVA Therapy
Skin - cytology
Skin - immunology
Skin, nail, hair, dermoskeleton
Various treatments
Chemotherapy
Skin disease
Langerhans cell
Psoriasis
Online AccessGet full text

Cover

More Information
Summary:Using OKT6 monoclonal antibody, we investigated the number of epidermal Langerhans' cells (LCs) in involved skin from patients with psoriasis, before and after mechlorethamine (HN2) or PUVA treatment. The number of LCs remained at about pretreatment number during three weeks of HN2 treatment alone, though they were reduced after 10 systemic PUVA treatments. Therefore, in contrast to PUVA which influences LCs, HN2 seems to have little effect on LCs. LCs in psoriatic plaques were, in number, 3-4 times less numerous than those in uninvolved, nontreated epidermis.
ISSN:0001-5555
1651-2057
DOI:10.2340/0001555567532535